Skip to main content

Table 1 Current anti-VEGF agents on retinal diseases

From: Diabetic macular edema: new concepts in patho-physiology and treatment

Anti-VEGF agents Mode of action Molecular weight (kDa) The phase III trail Year approved by FDA
Pegaptanib 28-base ribonucleic aptamer 50 Vision trial 2004 for wet AMD
Ranibizumab (Lucentis, Genetech) a monoclonal antibody fragment (Fab) derived from bevacizumab 50 Anchor, marina, pier (wet AMD) Ride/rice(DME) 2006 approved by FDA for wet AMD 2012approved by FDA for diabetic macular edema
Bevacizumab (Avastin, Genetech) Humanized anti-VEGF mAb, specific against VEGF165. It was first used as an adjunct treatment for metastatic colon cancer 149 None for eye diseases 2004 approved by FDA for colorectal cancer
Aflibercept (Elya, (Regeneron Pharmaceuticals) VEGF-Trap Recombinant VEGFR fusion protein that binds VEGFA and B,PGF 115 VIEW 1 and VIEW2 for wet AMD 2011 approved by FDA for wet AMD 2012 European Medicines Agency approved for AMD
KH902 (Chengdu Kanghong Biotechnology Co. Ltd) A humanized fusion protein that binds all forms of VEGFA,VEGF receptor 1 and 2 and the Fc portion of IgG1 143 Lamp, phoenix 2013 approved by cFDA for wet AMD
  1. AMD age related macular degeneration.
  2. FDA food and drug administration.